CN115429727A - Pet oral cavity repairing tooth cleaning water and preparation method thereof - Google Patents
Pet oral cavity repairing tooth cleaning water and preparation method thereof Download PDFInfo
- Publication number
- CN115429727A CN115429727A CN202210968638.9A CN202210968638A CN115429727A CN 115429727 A CN115429727 A CN 115429727A CN 202210968638 A CN202210968638 A CN 202210968638A CN 115429727 A CN115429727 A CN 115429727A
- Authority
- CN
- China
- Prior art keywords
- repairing
- oral cavity
- agent
- pet
- pets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000214 mouth Anatomy 0.000 title claims abstract description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 41
- 238000004140 cleaning Methods 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000002131 composite material Substances 0.000 claims abstract description 35
- 150000001875 compounds Chemical class 0.000 claims abstract description 33
- 239000000551 dentifrice Substances 0.000 claims abstract description 32
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 30
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 claims abstract description 28
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 26
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 26
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 24
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 24
- 239000012752 auxiliary agent Substances 0.000 claims abstract description 24
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 22
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 22
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 20
- 206010052428 Wound Diseases 0.000 claims abstract description 19
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 15
- 241000028204 Vincetoxicum atratum Species 0.000 claims abstract description 15
- 239000011734 sodium Substances 0.000 claims abstract description 15
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 15
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims abstract description 15
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960000281 trometamol Drugs 0.000 claims abstract description 15
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 14
- 229960000458 allantoin Drugs 0.000 claims abstract description 14
- 229960002350 guaiazulen Drugs 0.000 claims abstract description 14
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 claims abstract description 13
- 229940051810 licorice root extract Drugs 0.000 claims abstract description 13
- 235000020725 licorice root extract Nutrition 0.000 claims abstract description 13
- 206010061218 Inflammation Diseases 0.000 claims abstract description 10
- 230000004054 inflammatory process Effects 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 238000003756 stirring Methods 0.000 claims description 25
- 239000007788 liquid Substances 0.000 claims description 11
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 9
- 230000002335 preservative effect Effects 0.000 claims description 9
- 229950002760 sodium gualenate Drugs 0.000 claims description 8
- GEYJUFBPCGDENK-UHFFFAOYSA-M sodium;3,8-dimethyl-5-propan-2-ylazulene-1-sulfonate Chemical compound [Na+].CC(C)C1=CC=C(C)C2=C(S([O-])(=O)=O)C=C(C)C2=C1 GEYJUFBPCGDENK-UHFFFAOYSA-M 0.000 claims description 8
- -1 compound amino acid salt Chemical class 0.000 claims description 7
- 229910019142 PO4 Inorganic materials 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 239000010452 phosphate Substances 0.000 claims description 6
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 5
- 244000025254 Cannabis sativa Species 0.000 claims description 5
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 5
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 5
- 235000009120 camo Nutrition 0.000 claims description 5
- 235000005607 chanvre indien Nutrition 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000011487 hemp Substances 0.000 claims description 5
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 5
- 229940027779 persimmon extract Drugs 0.000 claims description 5
- 235000015278 beef Nutrition 0.000 claims description 4
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims description 2
- UAGFTQCWTTYZKO-WCCKRBBISA-N (2s)-pyrrolidine-2-carboxylic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H]1CCCN1 UAGFTQCWTTYZKO-WCCKRBBISA-N 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical class [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 claims description 2
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 2
- 235000019982 sodium hexametaphosphate Nutrition 0.000 claims description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 claims description 2
- 235000019832 sodium triphosphate Nutrition 0.000 claims description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000029663 wound healing Effects 0.000 abstract description 3
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 19
- 238000012360 testing method Methods 0.000 description 14
- 239000013642 negative control Substances 0.000 description 12
- 239000013641 positive control Substances 0.000 description 10
- 230000028327 secretion Effects 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 102000004890 Interleukin-8 Human genes 0.000 description 7
- 108090001007 Interleukin-8 Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 235000019629 palatability Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000006558 Dental Calculus Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 206010044029 Tooth deposit Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a pet oral cavity repairing and tooth cleaning water, which comprises the following components: the compound anti-inflammatory agent comprises licorice root extract, allantoin and cynanchum atratum extract, a compound repairing agent comprising beta-glucan, recombinant protein and guaiazulene sodium sulfonate, tromethamine, a functional auxiliary agent and a proper amount of water, and the oral cavity repairing and tooth cleaning water for pets has the beneficial effects of resisting inflammation and promoting wound healing. The invention discloses a preparation method of a pet oral cavity repairing tooth cleaning water, which comprises the following steps: after the beta-glucan, the recombinant protein and the water in the composite repairing agent are stirred and mixed, the composite anti-inflammatory agent and the functional auxiliary agent are added and stirred until the mixture is transparent and viscous, then the guaiazulene sodium sulfonate and the tromethamine are added and stirred uniformly, the preparation method is simple, and the prepared oral repairing tooth cleaning water for pets is nontoxic. The invention discloses a product for preparing a pet oral cavity repairing dentifrice for treating oral inflammation and wound surfaces of pets.
Description
Technical Field
The invention relates to the field of pet oral cavity repair. More particularly, the invention relates to a pet oral cavity repairing tooth cleaning water and a preparation method thereof.
Background
In the global dental guidelines of the World Small Animal Veterinary Association (WSAVA) issued by the World Small Animal Veterinary Association (WSAVA), oral problems begin to appear in 70% of cats and 80% of dogs at the age of 2, the diagnosis reasons of the oral problems of the pets are mostly related to oral inflammation or dental calculus, the related operations in the diagnosis and treatment process are extremely easy to form wounds or cause infection, at present, the inflammation infection can be reduced only by applying medicines to the wounds, but the matching degree of the pets is low, and the medicine effect is not good. Therefore, it is desirable to design the formulation of oral cavity repairing drugs for pets to achieve the beneficial effects of resisting inflammation and promoting wound healing.
Disclosure of Invention
An object of the present invention is to solve at least the above problems and to provide at least the advantages described later.
To achieve these objects and other advantages in accordance with the purpose of the invention, there is provided a pet oral cavity repairing dentifrice comprising the following components: the compound anti-inflammatory agent comprises licorice root extract, allantoin and cynanchum atratum extract, a compound repairing agent comprising beta-glucan, recombinant protein and guaiazulene sodium sulfonate, tromethamine, a functional auxiliary agent and a proper amount of water.
Preferably, the content of the compound anti-inflammatory agent is 0.1-1.0 wt% of licorice root extract, 0-0.05 wt% of allantoin and 1.0-5.0 wt% of cynanchum atratum extract, the content of the compound repairing agent is 0.1-1.0 wt% of beta-glucan, 0.1-1.0 wt% of recombinant protein and 0.1-1.0 wt% of sodium guaazulene sulfonate, the content of tromethamine is 0-1.0 wt%, the content of the functional auxiliary agent is 1.2-7.01 wt%, and the balance is water.
Preferably, the functional auxiliary agent comprises the following components in percentage by mass:
0.2 to 2.0 percent of compound preservative, wherein the compound preservative comprises 0.1 to 1.0 percent of 1, 2-hexanediol and 0.1 to 1.0 percent of p-hydroxyacetophenone;
0.1 to 1.01 percent of composite palatant, wherein the composite palatant comprises 0 to 0.5 percent of phosphate, 0.1 to 0.5 percent of composite amino acid salt and 0 to 0.01 percent of beef essence.
Preferably, the functional auxiliary agent further comprises 1.0-5.0 wt% of glycerin, 0.1-1.0 wt% of hemp leaf extract and 0.1-1.0 wt% of persimmon extract.
Preferably, the phosphate is one or more of sodium pyrophosphate, sodium hexametaphosphate, sodium tripolyphosphate, disodium hydrogen phosphate and sodium dihydrogen phosphate.
Preferably, the compound amino acid salt is one or more of L-sodium glutamate, histidine hydrochloride, proline hydrochloride and cystine salt.
Preferably, the beta-glucan has a molecular weight of 200 to 250 kilodaltons.
The preparation method of the pet oral cavity repairing tooth cleaning water comprises the following steps:
step one, heating beta-glucan, recombinant protein and water in the composite repairing agent to 80-90 ℃, stirring and mixing for 30-45 min, adding the composite anti-inflammatory agent when the temperature is reduced to 30-45 ℃, stirring until the composite anti-inflammatory agent is dissolved, adding the functional auxiliary agent, and stirring until the mixture is transparent and viscous to obtain liquid 1;
step two, adding the guaiazulene sodium sulfonate in the composite repairing agent into the liquid 1, uniformly stirring, adding tromethamine, and uniformly stirring to obtain the oral repairing and tooth cleaning water for pets.
Provides a pet oral cavity repairing dentifrice for preparing a product for treating oral inflammation of pets.
Provides a pet oral cavity repairing and tooth cleaning water for preparing a product for treating oral cavity wounds of pets.
The invention at least comprises the following beneficial effects:
firstly, compared with the prior art, the licorice root extract, the allantoin and the cynanchum atratum extract in the pet oral cavity repairing dentifrice provided by the invention are synergistically combined together to play a role in relieving inflammation, and are not invaded by pathogenic bacteria, so that the wound is quickly repaired, and the anti-allergy capability is improved.
Secondly, the beta-glucan, the recombinant protein and the guaiazulene sodium sulfonate in the pet oral cavity repairing and tooth cleaning water provided by the invention act synergistically together, so that the stability of the guaiazulene sodium sulfonate is improved, the medicament efficacy is fully exerted, and excellent antibacterial, anti-inflammatory and wound repairing functions are achieved.
Thirdly, compared with the prior art that the inflammation infection is reduced by smearing the medicine on the wound, the oral cavity repairing tooth cleaning water for the pet, provided by the invention, is safe in components and non-toxic, and the pet can repair the wound by gargling or taking the oral cavity repairing tooth cleaning water for the pet directly.
Additional advantages, objects, and features of the invention will be set forth in part in the description which follows and in part will become apparent to those having ordinary skill in the art upon examination of the following or may be learned from practice of the invention.
Detailed Description
The present invention is further described in detail below with reference to examples so that those skilled in the art can practice the invention with reference to the description.
It should be noted that the experimental methods described in the following embodiments are all conventional methods unless otherwise specified, and the reagents and materials described therein are commercially available unless otherwise specified.
< example 1>
The pet oral cavity repairing tooth cleaning water comprises the following components: the compound anti-inflammatory agent comprises licorice root extract, allantoin and cynanchum atratum extract, a compound repairing agent comprising beta-glucan, recombinant protein and guaiazulene sodium sulfonate, tromethamine, a functional auxiliary agent and a proper amount of water.
The content of the composite anti-inflammatory agent is 0.1wt% of licorice root extract and 1.0wt% of cynanchum atratum extract, the content of the composite repairing agent is 0.1wt% of beta-glucan, 0.1wt% of recombinant protein, 0.1wt% of sodium guaiazulene sulfonate, the content of the functional auxiliary agent is 1.5wt%, and the content of water is 97.1wt%.
The functional auxiliary agent comprises the following components in percentage by mass:
0.2 percent of compound preservative, wherein the compound preservative comprises 0.1 percent of 1, 2-hexanediol and 0.1 percent of p-hydroxyacetophenone;
0.1% of compound palatability agent, and the compound palatability agent comprises 0.1% of compound amino acid salt.
The functional auxiliary agent also comprises 1.0wt% of glycerin, 0.1wt% of hemp leaf extract and 0.1wt% of persimmon extract.
Preparing the oral cavity repairing tooth cleaning water for the pet according to the following steps:
step one, heating beta-glucan, recombinant protein and water in the composite repairing agent to 80 ℃, stirring and mixing for 30min, adding the composite anti-inflammatory agent when the temperature is reduced to 30 ℃, stirring until the composite anti-inflammatory agent is dissolved, adding the functional auxiliary agent, and stirring until the mixture is transparent and viscous to obtain liquid 1;
step two, adding the guaiazulene sodium sulfonate in the composite repairing agent into the liquid 1, uniformly stirring, and uniformly stirring to obtain the oral repairing tooth cleaning water for pets.
< example 2>
The pet oral cavity repairing dentifrice comprises the following components: the compound anti-inflammatory agent comprises licorice root extract, allantoin and cynanchum atratum extract, a compound repairing agent comprising beta-glucan, recombinant protein and guaiazulene sodium sulfonate, tromethamine, a functional auxiliary agent and a proper amount of water.
The compound anti-inflammatory agent comprises 0.5wt% of licorice root extract, 0.025wt% of allantoin and 2.5wt% of cynanchum atratum extract, the compound repairing agent comprises 0.5wt% of beta-glucan, 0.5wt% of recombinant protein, 0.5wt% of sodium guaiazulene sulfonate, 0.5wt% of tromethamine, 5.005wt% of functional auxiliary agent and 89.97wt% of water.
The functional auxiliary agent comprises the following components in percentage by mass:
1% of compound preservative, wherein the compound preservative comprises 0.5% of 1, 2-hexanediol and 0.5% of p-hydroxyacetophenone;
0.505% of composite palatability agent, which comprises 0.25% of phosphate, 0.25% of composite amino acid salt and 0.005% of beef flavor by weight.
The functional auxiliary agent also comprises 2.5wt% of glycerin, 0.5wt% of hemp leaf extract and 0.5wt% of persimmon extract.
Preparing the oral cavity repairing tooth cleaning water for the pet according to the following steps:
step one, heating beta-glucan, recombinant protein and water in the composite repairing agent to 85 ℃, stirring and mixing for 47min, adding the composite anti-inflammatory agent when the temperature is reduced to 37 ℃, stirring until the composite anti-inflammatory agent is dissolved, adding the functional auxiliary agent, and stirring until the mixture is transparent and viscous to obtain liquid 1;
step two, adding the guaiazulene sodium sulfonate in the composite repairing agent into the liquid 1, stirring uniformly, adding tromethamine, and stirring uniformly to obtain the oral repairing tooth cleaning water for pets.
< example 3>
The pet oral cavity repairing tooth cleaning water comprises the following components: the compound anti-inflammatory agent comprises licorice root extract, allantoin and cynanchum atratum extract, a compound repairing agent comprising beta-glucan, recombinant protein and guaiazulene sodium sulfonate, tromethamine, a functional auxiliary agent and a proper amount of water.
The compound anti-inflammatory agent comprises 1.0wt% of licorice root extract, 0.05wt% of allantoin and 5.0wt% of cynanchum atratum extract, the compound repairing agent comprises 1.0wt% of beta-glucan, 1.0wt% of recombinant protein and 1.0wt% of sodium guaiazulene sulfonate, the tromethamine comprises 1.0wt%, the functional auxiliary agent comprises 10.01wt% and the water comprises 79.94wt%.
The functional auxiliary agent comprises the following components in percentage by mass:
2.0% of compound preservative, 1.0% of 1, 2-hexanediol and 1.0% of p-hydroxyacetophenone;
1.01 percent of compound palatant, wherein the compound palatant comprises 0.5 percent of phosphate, 0.5 percent of compound amino acid salt and 0.01 percent of beef flavor.
The functional auxiliary agent also comprises 5.0wt% of glycerin, 1.0wt% of hemp leaf extract and 1.0wt% of persimmon extract.
Preparing the oral cavity repairing tooth cleaning water for the pet according to the following steps:
step one, heating beta-glucan, recombinant protein and water in the composite repairing agent to 90 ℃, stirring and mixing for 45min, adding the composite anti-inflammatory agent when the temperature is reduced to 45 ℃, stirring until the composite anti-inflammatory agent is dissolved, adding the functional auxiliary agent, and stirring until the mixture is transparent and viscous to obtain liquid 1;
step two, adding the guaiazulene sodium sulfonate in the composite repairing agent into the liquid 1, uniformly stirring, adding tromethamine, and uniformly stirring to obtain the oral repairing and tooth cleaning water for pets.
< test on toxicity of product >
Inoculating human gingival fibroblast to 24-well plate, at 37 deg.C, 5% CO 2 The incubator of (1) was incubated overnight, a series of graded concentrations of oral cavity repairing dentifrice for pets prepared according to example 3, a concentration of dexamethasone, a blank solution were set and administered to human gingival fibroblasts, the relative viability of the cells was determined using the thiazole blue (MTT) colorimetric method, and the toxicity was tested, and the test data was processed to obtain the results shown in table 1 below, wherein the analysis of the results in the group is expressed as mean and standard deviation, and the statistical analysis of t-test was used for each group comparison:
TABLE 1 MTT assay results
As shown in the MTT detection results in Table 1, the pet oral cavity repairing dentifrice developed by the present invention is based on human gingival fibroblasts, and the relative viability of the cells is not significantly reduced in the concentration range of 5%, so it is analyzed that the pet oral cavity repairing dentifrice provided by the present invention does not exhibit cytotoxicity in the concentration range of 5%.
< comparative example 1>
The composition, content and preparation method of the oral cavity repairing dentifrice for pets are the same as example 3, except that the anti-inflammatory agent is 0.05wt% of allantoin and 6.0wt% of cynanchum atratum extract, and the glycyrrhiza uralensis extract is not contained.
< comparative example 2>
The composition, content and preparation method of the oral cavity repairing dentifrice for pets are the same as example 3, except that the anti-inflammatory agent is 1.0wt% of Glycyrrhizae radix extract and 5.05wt% of Cynanchum atratum extract, and allantoin is not contained.
< test of anti-inflammatory Properties of products >
1. Test method
(1) Inoculation: by 4X 10 4 Inoculation Density of Individual/well human gingival fibroblasts into 24-well plates at 37 ℃ 5% CO 2 Was incubated overnight in the incubator of (1).
(2) Preparing liquid: a1 ng/mL solution of proinflammatory cytokines (1L-1 α), 0.01% (v/v) dexamethasone as a positive control solution, 5% (v/v) comparative example 1, 5% (v/v) comparative example 2, and 5% (v/v) pet oral cavity repair dentifrice as prepared in example 3 were prepared as sample group solutions according to the test protocol of Table 2 below.
TABLE 2 test protocol
| Group of | Sample name | Concentration of sample | Induction conditions |
| Blank group | / | / | / |
| Negative control group | / | / | 1L-1α |
| Positive control group | Dexamethasone | 0.01％(v/v) | 1L-1α |
| Comparative example 1 | Oral cavity repairing dentifrice for pet in comparative example 1 | 5％(v/v) | 1L-1α |
| Comparative example 2 | Comparative example 2 oral cavity repairing dentifrice for pets | 5％(v/v) | 1L-1α |
| Example 3 | Oral cavity repairing dentifrice of example 3 for pets | 5％(v/v) | 1L-1α |
(3) Administration of drugsAnd stimulation: when the plating rate of cells in 24-well wells reached 40% -50%, the wells were subjected to group stimulation and dosing according to the test protocol of Table 1, with 1mL per well, 3 replicate wells per group, and CO 5% at 37% 2 The incubator of (1) was incubated for 24h.
(4) Collecting cell supernatant: after 24h of culture, the cell supernatant was collected in a microcentrifuge tube and stored frozen at-80 ℃.
(5) Enzyme linked immunosorbent assay (ELISA): and detecting the content change of proinflammatory factors (IL-6 and IL-8) expressing inflammatory response in cell supernatant according to the operation instructions of the IL-6ELISA kit and the IL-8ELISA kit.
2. Test results
2.1 supernatant collection of the affected human gingival fibroblasts, detection of IL-6 content was performed according to kit instructions, and the data were processed as shown in table 3 below, wherein the analysis of results in the group was expressed by standard deviation, and the comparison between the groups was performed by statistical t-test analysis (significance was # in the case of comparing with the blank group, P-value < 0.05 was #, P-value < 0.01 was # and significance was # in the case of comparing with the negative control, P-value < 0.05 was # and P-value < 0.01 was #):
TABLE 3 IL-6 test results table
| Group of | Average concentration (pg/mL) | Standard deviation of | P-value |
| Blank group | 57.84 | 7.45 | / |
| Negative control group | 54971.12 | 1889.64 | 0.0000## |
| Positive control group | 11550.74 | 535.85 | 0.0000** |
| Comparative example 1 | 50987.47 | 1221.23 | 0.00** |
| Comparative example 2 | 39590.83 | 1315.51 | 0.00** |
| Example 3 | 10972.66 | 332.84 | 0.0000** |
As can be seen from the data in Table 3, compared with the blank control group, the IL-6 secretion level of the negative control group is very significantly increased (P is less than 0.01), which indicates that the 1L-1 alpha stimulation can very significantly improve the IL-6 secretion amount, and indicates that the 1L-1 alpha stimulation condition of the test is effective; compared with a negative control group, the IL-6 secretion level of the positive control group is extremely reduced remarkably (P is less than 0.01), which indicates that the positive control of the test is effective; compared with a negative control group, the IL-6 secretion levels of the comparative example 1, the comparative example 2 and the example 3 are also extremely remarkably reduced (P is less than 0.01), wherein the effect of the example 3 is more excellent, and the analysis reason is probably that the composite anti-inflammatory agent formed by the synergistic action of the licorice root extract, the cynanchum atratum extract and the allantoin achieves the effect of relieving inflammation, the reduction effect of the example 3 is even better than that of the existing anti-inflammatory agent dexamethasone in the positive control group, and the result shows that the oral cavity repairing dentifrice for pets can achieve the effective anti-inflammatory effect.
2.2 supernatant collection of human gingival fibroblasts after the effect of the blank group, the negative control group, the positive control group and the example 3, detection of the content of IL-8 was performed according to the kit instructions, and the detection data were processed as shown in the following table 4, wherein the analysis of results in the groups was expressed by standard deviation, and the comparison between the groups was performed by t-test statistical analysis (the significance was # compared with the blank group, P-value < 0.05 was #, P-value < 0.01 was # and the significance was # compared with the negative control group, P-value < 0.05 was # and P-value < 0.01 was #):
TABLE 4 IL-8 TEST RESULTS TABLE
| Group of | Average concentration (pg/mL) | Standard deviation of | P-value |
| Blank group | 98.52 | 3.64 | / |
| Negative control group | 138339.79 | 5600.68 | 0.000## |
| Positive control group | 56633.90 | 1766.31 | 0.000** |
| Example 3 | 92336.07 | 1448.51 | 0.000** |
As can be seen from the data in Table 4, compared with the blank control group, the IL-8 secretion level of the negative control group is remarkably increased (P is less than 0.01), which indicates that the 1L-1 alpha stimulation can remarkably improve the IL-8 secretion amount, and indicates that the 1L-1 alpha stimulation condition is effective in the test; compared with a negative control group, the IL-8 secretion level of the positive control group is extremely reduced remarkably (P is less than 0.01), which indicates that the positive control of the test is effective; the level of IL-8 secretion in example 3 was also very significantly reduced compared to the negative control group (P < 0.01), which also indicates that the oral care dentifrice for pets is effective in anti-inflammatory.
< comparative example 3>
The components, content and preparation method of the oral cavity repairing dentifrice for pets are the same as those in example 3, wherein the difference is that the content of the composite repairing agent is 3.0wt% of sodium guaiazulene sulfonate, and the oral cavity repairing dentifrice does not contain beta-glucan and recombinant protein.
< comparative example 4>
The components, content and preparation method of the oral cavity repairing dentifrice for pets are the same as example 3, wherein the difference is that the composite repairing agent content is 3.0wt% of beta-glucan, and the composite repairing agent does not contain sodium guaiazulene sulfonate and recombinant protein.
< comparative example 5>
The composition, content and preparation method of the oral cavity repairing dentifrice for pets are the same as those in example 3, wherein the difference is that the content of the composite repairing agent is 3.0wt% of recombinant protein, and the oral cavity repairing dentifrice does not contain beta-glucan and sodium guaiazulene sulfonate.
< test of repair Performance of product >
Animal experiments were carried out on the pet oral cavity repairing dentifrice prepared in example 1, example 2, example 3, comparative example 4 and comparative example 5 to compare the wound healing promoting effect thereof, and the specific experimental protocol was as follows:
depilating the back of rat, marking 1.6cm diameter and 2cm area at two sides of back spine, parallel to the spine at head and tail ends 2 The circular incision line of (1). After skin is disinfected by iodophor, the skin is cut off to the shallow layer by scissors along the marking line, and 2 circular wound surfaces are formed. The left wound is externally applied with the oral cavity repairing tooth cleaning water for pets prepared in examples or comparative examples, and the right wound is not treated and used as a control group, and is wrapped by covering with gauze. The wound area ratios on both sides relative to the wound area on the first day in observations on days 1,2, 4, 6, 8, 10 after treatment are shown in table 5:
TABLE 5 wound area ratio (%)/day one wound area on both sides of mouse
As can be seen from the data in table 5, the composite repairing agent formed by matching the β -glucan, the recombinant protein and the sodium guaiazulene sulfonate in the example has better using effect and a preferable range compared with the comparative example, and the example 3 has better wound repairing effect compared with the examples 1 and 2. Therefore, the oral cavity repairing dentifrice disclosed by the invention can be used for rapidly repairing the injury of the oral cavity wound and promoting the growth and healing of the wound.
While embodiments of the invention have been described above, it is not limited to the applications set forth in the description and the embodiments, which are fully applicable to various fields of endeavor for which the invention may be embodied with additional modifications as would be readily apparent to those skilled in the art, and the invention is therefore not limited to the details given herein and to the embodiments shown and described without departing from the generic concept as defined by the claims and their equivalents.
Claims (10)
1. The pet oral cavity repairing tooth cleaning water is characterized by comprising the following components:
the compound anti-inflammatory agent comprises licorice root extract, allantoin and cynanchum atratum extract, a compound repairing agent comprising beta-glucan, recombinant protein and guaiazulene sodium sulfonate, tromethamine, a functional auxiliary agent and a proper amount of water.
2. The oral cavity repairing dentifrice for pets as claimed in claim 1, wherein the complex anti-inflammatory agent comprises 0.1-1.0 wt% of licorice root extract, 0-0.05 wt% of allantoin, 1.0-5.0 wt% of cynanchum atratum extract, the complex repairing agent comprises 0.1-1.0 wt% of beta-glucan, 0.1-1.0 wt% of recombinant protein, 0.1-1.0 wt% of sodium guaiazulene sulfonate, the tromethamine comprises 0-1.0 wt%, the functional adjuvant comprises 1.2-7.01 wt%, and the balance is water.
3. The pet oral care dentifrice of claim 1, wherein the functional adjunct comprises, in mass percent:
0.2 to 2.0 percent of compound preservative, wherein the compound preservative comprises 0.1 to 1.0 percent of 1, 2-hexanediol and 0.1 to 1.0 percent of p-hydroxyacetophenone;
0.1 to 1.01 percent of compound palatant, wherein the compound palatant comprises 0 to 0.5 percent of phosphate, 0.1 to 0.5 percent of compound amino acid salt and 0 to 0.01 percent of beef flavor.
4. The pet oral care dentifrice of claim 1 wherein the functional aid further comprises glycerin 1.0 to 5.0wt%, hemp leaf extract 0.1 to 1.0wt%, persimmon extract 0.1 to 1.0wt%.
5. The pet oral care dentifrice of claim 3, wherein the phosphate is one or more of sodium pyrophosphate, sodium hexametaphosphate, sodium tripolyphosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate.
6. The pet oral cavity repairing dentifrice of claim 3, wherein said complex amino acid salt is one or more of sodium L-glutamate, histidine hydrochloride, proline hydrochloride, cystine salt.
7. The pet oral care dentifrice of claim 1 wherein the β -glucan has a molecular weight of 200 to 250 ten thousand daltons.
8. The method of preparing a pet oral cavity-repairing dentifrice of claim 1, comprising the steps of:
step one, heating beta-glucan, recombinant protein and water in the composite repairing agent to 80-90 ℃, stirring and mixing for 30-45 min, adding the composite anti-inflammatory agent when the temperature is reduced to 30-45 ℃, stirring until the composite anti-inflammatory agent is dissolved, adding the functional auxiliary agent, and stirring until the mixture is transparent and viscous to obtain liquid 1;
step two, adding the guaiazulene sodium sulfonate in the composite repairing agent into the liquid 1, stirring uniformly, adding tromethamine, and stirring uniformly to obtain the oral repairing tooth cleaning water for pets.
9. The use of a pet oral care dentifrice as claimed in any one of claims 1 to 7 in the manufacture of a product for the treatment of oral inflammation in pets.
10. The oral care dentifrice for pets, as claimed in any one of claims 1 to 7, for use in the preparation of a product for treating oral wounds in pets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210968638.9A CN115429727A (en) | 2022-08-12 | 2022-08-12 | Pet oral cavity repairing tooth cleaning water and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210968638.9A CN115429727A (en) | 2022-08-12 | 2022-08-12 | Pet oral cavity repairing tooth cleaning water and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115429727A true CN115429727A (en) | 2022-12-06 |
Family
ID=84242671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210968638.9A Pending CN115429727A (en) | 2022-08-12 | 2022-08-12 | Pet oral cavity repairing tooth cleaning water and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115429727A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602183A (en) * | 1991-03-01 | 1997-02-11 | Warner-Lambert Company | Dermatological wound healing compositions and methods for preparing and using same |
| RU2141817C1 (en) * | 1998-04-16 | 1999-11-27 | Геннадий Федорович Федорин | "phytodent" composition for treating mouth cavity and throat diseases |
| CN103385802A (en) * | 2012-05-11 | 2013-11-13 | 潘申权 | Solution product and combined product alleviating or removing stomatitis nodules and stomatitis spots, and application thereof |
| CN109893464A (en) * | 2019-02-23 | 2019-06-18 | 中美杜克(广州)护肤研究中心(普通合伙) | It is a kind of to block the whitening spot-removing skin care item and preparation method thereof for inhibiting reduction melanin |
-
2022
- 2022-08-12 CN CN202210968638.9A patent/CN115429727A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602183A (en) * | 1991-03-01 | 1997-02-11 | Warner-Lambert Company | Dermatological wound healing compositions and methods for preparing and using same |
| RU2141817C1 (en) * | 1998-04-16 | 1999-11-27 | Геннадий Федорович Федорин | "phytodent" composition for treating mouth cavity and throat diseases |
| CN103385802A (en) * | 2012-05-11 | 2013-11-13 | 潘申权 | Solution product and combined product alleviating or removing stomatitis nodules and stomatitis spots, and application thereof |
| CN109893464A (en) * | 2019-02-23 | 2019-06-18 | 中美杜克(广州)护肤研究中心(普通合伙) | It is a kind of to block the whitening spot-removing skin care item and preparation method thereof for inhibiting reduction melanin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Aljady et al. | Biochemical study on the efficacy of Malaysian honey on inflicted wounds: an animal model | |
| CN117815181B (en) | Hoof and mouth spray for cattle and sheep with foot rot and preparation method and application thereof | |
| CN111514161B (en) | Anti-oral ulcer preparation and application thereof | |
| CN105012183B (en) | A kind of eucommia bark toothpaste and preparation method thereof | |
| CN113520896A (en) | Composition with acne removing and acne mark repairing functions and preparation method thereof | |
| CN101474284B (en) | External use medicament for treating fungal dermatopathy | |
| CN107375152A (en) | A kind of cation sterilization gel and preparation method thereof and the aloetic bacteriostatic gel product comprising the cation sterilization gel | |
| CN116492397B (en) | Preparation for improving cow breeding performance, preparation method thereof and method for improving cow breeding performance | |
| CN115429727A (en) | Pet oral cavity repairing tooth cleaning water and preparation method thereof | |
| CN1251738C (en) | Chinese medicine for treating ashen nail and its preparation method | |
| CN118575895A (en) | Application of Litsea cubeba essential oil in preparing products for preventing and treating tilapia agalactiae streptococcus disease and/or improving tilapia weight gain rate | |
| CN117224606A (en) | Compound for preventing and treating bacterial diseases of poultry and application thereof | |
| CN110960584B (en) | Foaming type cow hoof care liquid and preparation method thereof | |
| CN104906132B (en) | A kind of plaster for preventing and treating lamb stomatitis | |
| CN103463141A (en) | Chlorella spray | |
| CN112586441A (en) | African swine fever prevention and control method and application thereof | |
| US12097228B1 (en) | Mixture of cyanobacteria, chitosan, and plant extracts for wound healing and eliminating pathogen bacteria | |
| CN111990533A (en) | Fermented eucommia ulmoides leaf extract and application thereof in preparation of chicken feed | |
| CN113230205B (en) | Gynecological gel preparation and preparation method and application thereof | |
| CN114129493B (en) | Gastrodia elata washing-free antibacterial gel and preparation method and application thereof | |
| CN104906131B (en) | A kind of preparation method preventing and treating lamb stomatitis plaster | |
| RU2796674C1 (en) | Method of increasing the overall immunobiological reactivity of the body of calves | |
| CN116211781B (en) | Composition for preventing and treating chapped skin, and preparation method and application thereof | |
| CN115006312B (en) | Anti-inflammatory and antibacterial composition, application, product containing composition and preparation method of product | |
| CN109044933A (en) | It is a kind of with preventing and treating Resina Draconis toothpaste of diseases such as canker sore and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221206 |